26 September 2024
ValiRx PLC ("ValiRx" or the
"Company")
Conclusion of Evaluation
Project
London, UK - ValiRx Plc (AIM: VAL),
a life science company focusing on early-stage cancer therapeutics
and women's health, provides the following update at the conclusion
of the Evaluation project from the University of Barcelona
announced on 7 June 2023.
On entering the broader
collaboration agreement with Barcelona University in June 2023, the
Company tested drug candidates from the series "KRAS2" in a barrage
of in silico and
in vitro tests.
After expanding the series of molecules through in silico study, a selection of
candidates were synthesised and tested for anti-cancer activity as
a monotherapy and in combination with standard chemotherapy agents
within the laboratory at Inaphaea BioLabs Limited.
Although initial results show
promise, the development programme is at an early stage, and the
Company has decided to return the project to the university
researchers for further development, with no further financial
commitment from the Company. The parties have agreed to terminate
the current collaboration agreement and revert responsibility for
maintaining the intellectual property to Barcelona
University.
Mark Eccleston, CEO of ValiRx commented
"Working alongside the University of Barcelona
team on this project has been an engaging experience, and although
we are not in a position to progress with this lead series of
molecules at this stage, we look forward to retaining close contact
with the team at Barcelona to hear further updates on these and
other projects which could lead to future agreements."
The information contained within this
announcement is deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of
the Company take responsibility for this announcement.
*** ENDS
***
For more information, please
contact:
|
ValiRx
plc
Dr Mark Eccleston, CEO
|
Tel: +44 (0)
115 784 0026
www.valirx.com
Mark.eccleston@valirx.com
|
|
V
Formation (Public Relations)
Lucy Wharton - Senior PR Executive
Sue Carr - Director
|
+44 (0) 115
787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
|
Cairn
Financial Advisers LLP (Nominated Adviser)
Liam Murray / Ludovico Lazzaretti
|
Tel: +44 (0)
20 7213 0880
|
|
Shard Capital Partners LLP (Sole Broker)
Damon Heath
|
Tel:
+44 (0) 20 7186 9000
|
Notes for
Editors
About
ValiRx
ValiRx is a life science company focused on
early-stage cancer therapeutics and women's health, accelerating
the translation of innovative science into impactful medicines to
improve patient lives.
ValiRx provides the scientific, financial, and
commercial framework for enabling rapid translation of innovative
science into clinical development.
Using its extensive and proven experience in
research and drug development, the team at ValiRx selects and
incubates promising novel drug candidates and guides them through
an optimised process of development, from pre-clinical studies to
clinic and investor-ready assets.
ValiRx connects diverse disciplines across
scientific, technical, and commercial domains, with the aim of
achieving a more streamlined, less costly, drug development
process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for
science to advance.
Lead candidates from ValiRx's portfolio are
outlicensed or partnered with investors through ValiRx subsidiary
companies for further clinical development and
commercialisation.
ValiRx listed on the AIM Market of the London
Stock Exchange in October 2006 and trades under the ticker symbol:
VAL.
For further information, visit:
www.valirx.com